Alzheimer's Society Comment On New Data Observing The Cost Effectiveness Of Aricept (donepezil)

Main Category: Alzheimer's / Dementia
Article Date: 26 May 2009 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:3 stars

3 (1 votes)


New research presented at the annual meeting of ISPOR suggests that prescribing Aricept on diagnosis of either mild or moderate Alzheimer's disease would save the NHS money.

The National Institute for Health and Clinical Excellence (NICE) currently recommends that Aricept is not prescribed to people in the mild stages of Alzheimer's disease. This study, sponsored by Eisai, takes into account factors not considered by NICE, including cost of caregiver time. It suggests that savings to the NHS and society would be £7,100 per patient over a ten-year period if people with dementia are prescribed Aricept earlier.

A review of the NICE guidance is anticipated later this year.

'Alzheimer's Society has consistently stated that NICE's decision to deny people with dementia access to the only drugs for their condition is unethical and is based on flawed calculations. It disregards the difficulties associated with getting an accurate assessment in the early and middle stages and does not take into account factors such as the benefits treatments bring to carers.

This industry-funded research has examined the cost efficiency of prescribing one of these drugs in the early stages. It uses a complex financial model that considers a wider range of factors and concludes that prescribing this treatment would save NHS money.

NICE must tackle the flaws in its calculations to ensure people with dementia can get access to effective treatments. Alzheimer's Society hopes to see this addresses in the forthcoming review of the NICE guidance.'

Dr Susanne Sorensen
Head of Research
Alzheimer's Society

Full reference

Getslos, Blume, Ishak and Maclaine, Cost-effectiveness Study in Patients with Mild to Moderately Severe Alzheimer's Disease: Projected Benefits of Donepezil in the UK

Source
Alzheimer's Society

View drug information on ARICEPT.


Article adapted by Medical News Today from original press release.
Visit our alzheimer's / dementia section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Alzheimer's Society. "Alzheimer's Society Comment On New Data Observing The Cost Effectiveness Of Aricept (donepezil)." Medical News Today. MediLexicon, Intl., 26 May. 2009. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/151381.php>

APA
Alzheimer's Society. (2009, May 26). "Alzheimer's Society Comment On New Data Observing The Cost Effectiveness Of Aricept (donepezil)." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/151381.php.

Please note: If no author information is provided, the source is cited instead.


Alzheimer's / Dementia

What is Dementia?

The word dementia comes from the Latin de meaning "apart" and mens from the genitive mentis meaning "mind". Dementia is the progressive deterioration in cognitive function - the ability to process thought (intelligence). Read more...

What Is Alzheimer's Disease?

Alzheimer's disease is a progressive neurologic disease of the brain leading to the irreversible loss of neurons and the loss of intellectual abilities, including memory and reasoning. Read more...

Most Popular Articles



Follow Our Alzheimer's News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Alzheimer's / Dementia Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »